Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

HIV-Related Lymphoma Differs in Those With Early vs Advanced HIV Infection

April 1, 2002
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 4
Volume 11
Issue 4

HOUSTON-Physicians at Ben Taub General Hospital, Houston, noticed that an unusual number of patients were presenting with lymphoma as their first AIDS-defining event. This observation prompted a retrospective study of all HIV-positive patients with non-Hodgkin’s lymphoma presenting between 1989 and 2000.

HOUSTON—Physicians at Ben Taub General Hospital, Houston, noticed that an unusual number of patients were presenting with lymphoma as their first AIDS-defining event. This observation prompted a retrospective study of all HIV-positive patients with non-Hodgkin’s lymphoma presenting between 1989 and 2000.

Indeed, the analysis showed that 33 (35%) of the 88 patients identified in the study were newly diagnosed with HIV, whereas 55 were known to be HIV positive when their lymphoma was diagnosed, Suleiman Alfred Massarweh, MD, told ONI in an interview. In other cohorts of patients with HIV-related lymphoma, he noted, only 3% to 5% typically present with lymphoma as their first AIDS-defining illness.

This discrepancy may be explained, in part, by Ben Taub’s status as a community hospital. The hospital serves as the first destination for these patients at presentation, thus eliminating potential referral bias. "Most patients in the large cohorts already have their HIV diagnosis when they go to these referral centers," Dr. Massarweh said at the 43rd Annual Meeting of the American Society of Hematology (abstract 1434). He is a clinical fellow at Baylor College of Medicine.

The substantial number of newly diagnosed HIV patients with lymphoma in the Ben Taub database gave the Houston researchers a unique opportunity to compare these patients with lymphoma patients with known HIV infection.

Of the 55 known-HIV patients presenting with lymphoma in the study, 10 had no history of an AIDS-defining illness and were being followed by primary care physicians in the HIV clinic. The rest had a previous AIDS-defining event before their lymphoma presentation.

Burkitt’s Lymhoma

Dr. Massarweh noted that the new-HIV lymphoma patients tended to be a few years older than the known-HIV patients: an average of 41 vs 38 years.

A more important finding was that the new-HIV patients were significantly more likely to have Burkitt’s or Burkitt’s-like lymphoma. Conversely, the known-HIV patients, who typically were more immunocompromised, were more likely to have diffuse large B cell immunoblastic lymphoma.

In addition, gastrointestinal involvement was rare in the new-HIV patients, but was very strongly associated with known HIV. "Out of the 33 new-HIV patients, only one had GI involvement at diagnosis. The other 14 cases of GI involvement were in the known-HIV group," Dr. Massarweh said.

He noted that in most previous studies involving large cohorts, the investigators did not distinguish among different lymphoma types when determining trends in the incidence and outcome of AIDS-related lymphoma. "They put everything together," he said. "Central nervous system lymphoma should be out of the equation; it should be looked at separately because we know it occurs in very advanced patients with very low CD4 counts."

The Ben Taub cohort, he said, suggests that not all systemic lymphomas are the same either. "There is a variety that can develop in patients who do not have advanced immunosuppression, and this category may be amenable to treatments to reconstitute the immune system," he said. "These patients may be more likely to respond to their lymphoma therapy and have a chance of long survival."

The fact that patients with early HIV infection still develop lymphoma suggests, Dr. Massarweh said, that some pathogenetic pathway other than prolonged low CD4 counts may be responsible. "It might be due to other factors such as an endogenous cytokine imbalance," he said.

Articles in this issue

Infection Rate Low With Peripheral and Nontunneled CVCs Nontunneled Catheters
Virtual Shared Specimen Resource ‘Essential’
DHA Conjugate Increases Paclitaxel Uptake by Tumor Cells
Letrozole Superior to Tamoxifen in Metastatic Breast Cancer
S-8184 Paclitaxel Emulsion Promising in Phase I Study
HIV+ Veterans Have Higher Rates of Unusual Cancers
A Clinician’s Perspective on ASCO 2001: Going After the Epidermal Growth Factor Receptor
Online Breast Cancer Support Groups Beneficial
Survival Benefit With Capecitabine/Docetaxel
FDA Approves Zometa for Cancer-Related Bone Complications
New Blood Test for Early Ovarian Cancer in Clinical Trials
Race Per Se Does Not Predict Extracapsular Prostate Cancer
HIV-Related Lymphoma Differs in Those With Early vs Advanced HIV Infection
Equal Access Erases Racial Disparity in Prostate Cancer Stage
FDA Approves Zevalin for Use With Rituxan in Refractory NHL Patients
Recent Videos
Hydration and a healthy, well-balanced diet may mitigate fatigue among patients undergoing treatment for cancer.
The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.
Bland foods, such as crackers and chicken noodle soup, as well as fluids with electrolytes, may help stave off treatment-related nausea.
The toxicity profile of interferon and the limited availability of transplantation established a need for TKI development for chronic myeloid leukemia.
Related Content
Advertisement

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Kyle Doherty
September 8th 2025
Article

The median CNS PFS with Dato-DXd was 5.0 months vs 3.0 months with docetaxel in patients with NSCLC who have brain metastases.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.

Adjuvant Nivolumab/Chemo Reduces Recurrence Risk in Resected NSCLC

Roman Fabbricatore
September 8th 2025
Article

The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.


Man Up? The Truth About Men's Health After Cancer

Man Up? The Truth About Men's Health After Cancer

Daniel C. McFarland, DO;Christian J. Nelson, PhD
September 1st 2025
Podcast

Christian J. Nelson, PhD, dives into the complexities of sexual health concerns with men following cancer treatment, specifically with genitourinary cancers.


Ivonescimab plus chemotherapy following progression after a third-generation TKI showed consistent efficacy across EGFR-mutated NSCLC subgroups.

Ivonescimab/Chemo After TKI Progression Improves PFS in EGFR-Mutated NSCLC

Ashley Chan
September 8th 2025
Article

Ivonescimab plus chemotherapy following progression after a third-generation TKI showed consistent efficacy across EGFR-mutated NSCLC subgroups.


The overall safety profile of pirtobrutinib was consistent with previously reported trials across various CLL and SLL settings.

Pirtobrutinib Improves PFS in Treatment-Naïve CLL/SLL Without 17p Deletions

Tim Cortese
September 8th 2025
Article

Results from the phase 3 BRUIN CLL-313 trial show that OS trended favorably for pirtobrutinib vs chemoimmunotherapy in this CLL and SLL population.

Related Content
Advertisement

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Kyle Doherty
September 8th 2025
Article

The median CNS PFS with Dato-DXd was 5.0 months vs 3.0 months with docetaxel in patients with NSCLC who have brain metastases.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.

Adjuvant Nivolumab/Chemo Reduces Recurrence Risk in Resected NSCLC

Roman Fabbricatore
September 8th 2025
Article

The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.


Man Up? The Truth About Men's Health After Cancer

Man Up? The Truth About Men's Health After Cancer

Daniel C. McFarland, DO;Christian J. Nelson, PhD
September 1st 2025
Podcast

Christian J. Nelson, PhD, dives into the complexities of sexual health concerns with men following cancer treatment, specifically with genitourinary cancers.


Ivonescimab plus chemotherapy following progression after a third-generation TKI showed consistent efficacy across EGFR-mutated NSCLC subgroups.

Ivonescimab/Chemo After TKI Progression Improves PFS in EGFR-Mutated NSCLC

Ashley Chan
September 8th 2025
Article

Ivonescimab plus chemotherapy following progression after a third-generation TKI showed consistent efficacy across EGFR-mutated NSCLC subgroups.


The overall safety profile of pirtobrutinib was consistent with previously reported trials across various CLL and SLL settings.

Pirtobrutinib Improves PFS in Treatment-Naïve CLL/SLL Without 17p Deletions

Tim Cortese
September 8th 2025
Article

Results from the phase 3 BRUIN CLL-313 trial show that OS trended favorably for pirtobrutinib vs chemoimmunotherapy in this CLL and SLL population.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.